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transplantation can lead to BK virus associated nephropathy, 
which is so far only known from patients after kidney trans-
plantation.  © 2016 S. Karger AG, Basel 
 Introduction 
 Every year 50,000 patients receive stem cell transplan-
tation worldwide, but there is lack of data about urologi-
cal complications that occur when this therapy is insti-
tuted. Most studies were performed in paediatric stem 
cell transplantation or are retrospective analyses with a 
small number of cases  [1–7] . The complications men-
tioned were mostly urological infections and haematuria 
 [8] . Another complication that arises under this therapy 
is the BK virus–associated haemorrhagic cystitis, which 
can occur in 5–60% of the cases  [9, 10] . This disease can 
be severe and lead to higher morbidity  [11] . In univariate 
analysis, a myeloablative conditioning regimen has been 
identified as a risk factor for the development of BK vi-
rus–associated hemorrhagic cystitis under stem cell 
transplantation (p = 0.03, 95% CI 1.25–7.04)  [2] .
 Since urological complications can cause severe prob-
lems under allogenic stem cell transplantation with in-
creased morbidity and mortality, further investigations 
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 Abstract 
 Every year 50,000 patients receive a stem cell transplanta-
tion worldwide, but there is lack of data pertaining to uro-
logical complications.  Methods: We performed a retrospec-
tive analysis of all adult patients undergoing their first allo-
genic stem cell transplantation from January 2011 to 
June 2013 in our institution. Statistical tests performed were 
Pearson’s correlation, chi-square testing and logistic regres-
sion using SPSS 22.0.  Results: We identified 39 patients (22 
males, 17 females). Twenty four patients (61.5%) had a uro-
logical complication. Most frequent urologic complications 
were bacterial urinary tract infection (n = 13; 33.3%), acute 
renal failure (n = 6; 15.4%) and BK virus–associated haemor-
rhagic cystitis (n = 5; 12.8%). BK viruria was detected in 12 
patients (30.8%). We observed an association of creatinine 
increase (about 20 μmol/l at time of onset of BK viruria) with 
BK viruria (Pearson’s correlation 0.64; p = 0.01), and BK viruria 
is significantly linked to acute renal failure (Pearson’s correla-
tion 0.35; p = 0.029). In univariate regression, BK viruria is sig-
nificantly linked to urological complication (p = 0.025).  Con-
clusions: We suggest that BK virus infection during stem cell 
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especially by urologists are necessary. What is the preva-
lence of urological complications under stem cell trans-
plantation? When is a urological intervention required? 
What are the risk factors for the development of urologi-
cal complications, especially BK virus–associated hemor-
rhagic cystitis? These questions need to be answered to 
ensure the quality of urological patient care in stem cell 
transplantation.
 To fill this gap of knowledge, concerning the preva-
lence and risk factors for urological complications and to 
generate new hypotheses or research questions, we per-
formed a retrospective analysis of all adult patients un-
dergoing their first allogenic stem cell transplantation 
from January 2011 to June 2013 in our institution.
 Patients and Methods 
 Development of the Study and Study Population 
 The study was designed according to the guidelines in the syn-
thesis of qualitative research (ENTREQ) found on the equator-
network.org, an international initiative providing robust reporting 
guidelines  [12] .
 Then all patient records with demographic characteristics, pa-
tient history, blood and urine tests, and other related tests of adult 
patients with haematological disease undergoing their first allo-
genic stem cell transplantation from January 2011 to June 2013 in 
our institution were collected. The observation period was from 
the beginning of conditioning therapy to the end of in-patient stay. 
In case the in-patient stay was longer than day 70, day 70 after stem 
cell transplantation was the end of the observation period. No out-
patient data were included in this analysis.
 Afterward, a data bank of these patients was established.
 All procedures performed in this study were in accordance with 
the ethical standards of the institutional and/or national research 
committee and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. For this type of 
study, a formal consent was not required.
 Assessment of Infectious Complications 
 BK virus was assessed by quantitative PCR in urine (LightMix 
Polyoma JC-BK, manufacturer Tib Molbiol, Germany) on clinical 
suspicion only (mainly hemorrhagic cystitis); no other material 
(i.e. blood samples) was analysed for BK virus. CMV reactivation 
and urinary tract infections (UTIs) were assessed on a regular basis 
during in-house treatment. CMV was assessed at least 2 times a 
week by quantitative PCR; UTI was assessed at least 1 time a week 
by midstream urine sample and culture, both regardless of clinical 
signs or symptoms. BK virus–associated cystitis was defined as 
hemorrhagic cystitis with macrohaematuria in the presence of BK 
virus in urine.
 Statistical Analysis 
 Statistical calculations were performed using statistical package 
for the Social Sciences 22.0 software (SPSS Inc., Chicago, Ill., USA). 
Statistical tests used were Pearson’s correlation, chi-square testing 
and logistic regression.
 Day 0 of the timeline was defined as the day of infusion of the 
stem cell product. Time of leukopenia was defined as the interval 
from day 0 to the last day after allogeneic transplantation with a 
leukocyte count <1.0 × 10 9 /l. In the same way, time of thrombocy-
topenia was defined as the interval from day 0 to the last day after 
allogeneic transplantation with a platelet count <20 × 10 9 /l, fol-
lowed by a transfusion independent increase >20 × 10 9 /l.
 Results 
 Demographic Characteristics of the Study Population 
 We identified 39 patients (22 males and 17 females) 
undergoing their first allogenic stem cell transplantation 
due to haematological disease between January 2011 and 
June 2013 in our institution. The most frequent reason for 
stem cell transplantation was acute myeloid leukaemia 
(n = 10; 25.6%) followed by the heterogenic group of non-
Hodgkin’s lymphomas (n = 8; 20.5%). Urological diseas-
es in patient history were rare.  Table 1 shows the basic 
demographic characteristics of the study population.
 Conditioning Regime and Transplantation Data 
 The conditioning regimens used for allogenic stem 
transplantation in this study population are heterogenic. 
Thirty (76.9%) received a myeloablative conditioning and 
9 (23.1%) patients were conditioned with a reduced-in-
tense protocol. The mostly used regime for myeloablative 
conditioning is busulfan/cyclophosphamide/alemtuzum-
ab in 18 cases (46.2%). TBI was used in only 5 cases (12.8%). 
Seventy four percent of the conditioning regimes (n = 29) 
contained cyclophosphamide. In-vivo T-cell depletion as 
GvHD prophylaxis was performed with low-dose alemtu-
zumab  [13] in all patients during conditioning regimen.
 Antimicrobial prophylaxis followed standard guide-
lines. Briefly, the patients received third-generation qui-
nolones, acyclovir, TMP-SMZ and voriconazole or 
posaconazole  [14] .
 Mesna and forced diuresis were used as prophylaxis in 
all patients with cyclophosphamide as part of the condi-
tioning regimen.
 The transplantation data are shown in  table 2 . Cyclo-
sporine A (CsA) in conjunction with short-course meth-
otrexate or with mycophenolate-mofetil was used for im-
munosuppression and GvHD prophylaxis after stem cell 
transplantation in all patients. Acute GvHD until day 70 
occurred in 5 cases: 3 cases were acute GvHD of the skin 
NCI grade 1, one case acute GvHD of the skin NCI grade 
2 and one case acute GvHD of the bowel NCI grade 3. We 
observed only until day 70 due to the quality of retrospec-
tive data.
 Schneidewind/Neumann/Burchardt/
Krüger 
Urol Int 2016;97:434–439
DOI: 10.1159/000445124
436
 We noticed 5 CMV reactivations during the observa-
tion period; statistical analysis shows no correlation be-
tween CMV reactivation and BK associated hemorrhagic 
cystitis (Pearson’s correlation –0.243, p = 0.136).
 Urological Complications 
 Most frequent complications were bacterial UTI with 
at least 10 5 uropathogens/ml in midstream urine (n = 13; 
33.3%), acute renal failure according to the definition of 
the Acute Kidney Injury Network (n = 6; 15.4%) and BK 
virus–associated hemorrhagic cystitis (n = 5; 12.8%). No 
ureter stenosis was detected in our study population.
 In 11 patients with UTI, we found  Escherichia coli as 
pathogen, in 2 patients Enterococcus species. In the 2 pa-
tients who developed an urosepsis, we found  E. coli in 1 
patient and Enterococcus in 1 patient.
 No patient with an acute renal failure needed dialysis 
or other renal replacement therapies. We found no cor-
relation between acute renal failure and UTIs in our study 
population (Pearson’s correlation 0.298; p = 0.065).
 An overview of all urological complications is given in 
 table 3 .
 Kidney Function and BK Viruria 
 BK viruria was detected in 12 patients (30.8%). Six pa-
tients (15.4%) developed an acute renal failure, 4 of these 
6 patients had a BK viruria, and 2 patients developed an 
acute renal failure in the absence of BK viruria.
Table 1.  Demographic characteristics of the study population (n = 
39)
n (%)
Gender
Male 22 (56.4)
Female 17 (43.6)
Age, median 52
SD; min–max 12.97; 20–68
Primary disease
AML 10 (25.6)
NHL 8 (20.5)
AML arising from MDS 4 (10.2)
CML 3 (7.7)
Plasmoblastic lymphoma 2 (5.1)
MDS 2 (5.1)
Biphaenotypic leukemia 2 (5.1)
Aplastic anemia 1 (2.6)
T-PLL 1 (2.6)
Mantle cell lymphoma 1 (2.6)
Urolocigal disease in patient history
No disease 26 (66.7)
BOO 3 (7.7)
Urolithiasis 3 (7.7)
CKD 2 (5.1)
Recurrent UTI 2 (5.1)
Pretherapeutic chemotherapy
Yes 36 (93.3)
No 3 (7.7)
Pretherapeutic radiation
Yes 6 (15.4)
No 33 (84.6)
 AML = Acute myeloid leukemia; NHL = non-hodgkin lympho-
ma; MDS = myelodysplastic syndrome; CML = chronic myeloid 
leukemia; T-PLL = T-prolymphocytic leukemia; BOO = bladder 
outlet obstruction; CKD = chronic kidney disease.
Table 2.  Transplantation data of the study population (n = 39)
n (%)
Donor
Matched related donor 8 (20.5)
Mismatched unrelated donor 20 (51.3)
Matched unrelated donor 11 (28.2)
Duration of leucopenia, median 14
SD; min–max 4.15; 10–29
Duration of thrombopenia, median 20
SD; min–max 5.49; 8–33
Transfused packed red blood cells, median 6.0
SD; min–max 4.43; 0–20
Transfused packed platelets, median 3.0
SD; min–max 4.96; 0–23
Transfused fresh frozen plasma, median 0.0
SD; min–max 0.65; 0–4
Bearman toxicity kidney
0 27 (69.2)
1 9 (23.1)
2 3 (7.7)
3 0 (0)
4 0 (0)
Bearman toxicity bladder
0 36 (92.3)
1 0 (0)
2 2 (5.1)
3 1 (2.6)
4 0 (0)
Acute GvHD
Yes 5 (12.8)
No 34 (87.2)
Immunosuppression
CsA + MTX 27 (69.7)
CsA 6 (15.4)
CsA + MMF 4 (10.2)
CsA + MTX + MMF 2 (5.1)
 GvHD = Graft vs. host disease; MTX = methotrexate; MMF = 
mycophenolate mofetile.
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 There was a median increase of creatinine of 8.0 μmol/l 
at day 70 after allogenic stem cell transplantation in the 
group of patients with BK viruria. We observed an asso-
ciation of creatinine increase (about 20 μmol/l at the time 
of onset of BK viruria) with BK viruria (Pearson’s correla-
tion 0.64; p = 0.01) and also a significant association of 
BK viruria and acute renal failure (Pearson’s correlation 
0.35; p = 0.029).
 BK viruria occurs in mean 28 days after stem cell trans-
plantation (SD 14.05; 20–70).
 Figure 1 shows the development of creatinine during 
stem cell transplantation in comparison of the groups of 
patients with and without BK viruria.
 There is no link between bacterial UTI and BK viruria 
in this study population (Pearson’s correlation –0.17; p = 
0.298).
 BK viruria is significantly linked to myeloablative con-
ditioning regimen (Pearson’s correlation 0.365; p = 0.022) 
and to donor HLA mismatch (Pearson’s correlation 
0.354; p = 0.027).
 Risk Factors for Urological Complication 
 In univariate regression, BK viruria is significantly 
linked to urological complication (p = 0.025). We could 
not identify a significant risk factor for urological compli-
cation in multivariate analysis.
 Survival Data 
 The overall survival is shown in  figure 2 . There was no 
mortality due to a urological complication.
 Discussion 
 We performed an explorative retrospective analysis of 
urological complications under first allogenic stem cell 
transplantation of adults with haematological disease. To 
our knowledge this was the first study that focussed only 
on urological complications under this therapy.
 We must assume that this is still a small and hetero-
genic group of patients undergoing allogenic stem cell 
transplantation, but urological disease in patient history 
is rare.
 The main urological complications were UTI, acute 
renal failure and BK virus–associated haemorrhagic cys-
titis. We found similar results as in retrospective analyses 
with smaller sample sizes and from paediatric stem cell 
transplantation  [1–7] . Infectious complications like UTI 
are an expected problem under immunosuppression, and 
therefore, this result is not surprising.
Table 3.  Urological complications of the study population (n = 39)
n (%)
Urological complication
Yes 24 (61.5)
No 15 (38.5)
Intervention by a urologist 2 (5.1)
BK viruria 12 (30.8)
Complication
UTI (significant bacteriuria in midstream urine) 13 (33.3)
Sepsis due to UTI 2 (5.1)
BK virus–associated hemorrhagic cystitis 5 (12.8)
Acute renal failure 6 (15.4)
Pre-renal 1 (2.6)
Renal 5 (12.8)
Post-renal 0 (0)
Presence of BK viruria 4 (11.2)
 BK virus–associated haemorrhagic cystitis is defined as BK 
viruria with the presence of haematuria at the same time; acute 
renal failure is defined according to the definition of the Acute 
Kidney Injury Network.
 Fig. 1. Mean creatinine development under allogenic stem cell 
transplantation, comparison between patients with and without 
BK viruria. –1 day = before starting conditioning regime; 0 day = 
day of stem cell transplantation.
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 Interestingly, we could identify BK viruria as a risk fac-
tor for urological complication in univariate analysis, but 
we could not find a risk factor in multivariate regression 
(probably due to the limitations of a multivariate analysis 
in small sample sizes).
 Since we identified BK viruria as significantly linked to 
urological complication under allogenic stem cell trans-
plantation and BK virus–associated haemorrhagic cysti-
tis was one of the most frequent complications in our 
study population, we must mention that BK virus–associ-
ated hemorrhagic cystitis is a severe problem under stem 
cell transplantation. It can lead to higher mortality. Gilis 
et al.  [11] showed in their retrospective study of 323 stem 
cell–transplanted patients that BK virus–associated 
haemorrhagic cystitis can lead to a significant longer hos-
pitalisation time (p < 0.0001), significantly more trans-
fused packed red blood cells (p = 0.0003) and significant-
ly more transfused packed blood platelets (p < 0.0001). In 
our opinion, this disease needs further investigation from 
the urological side. For example, what is the right therapy 
for these patients?
 Several risk factors for BK virus–associated haemor-
rhagic cystitis have been identified so far: in retrospective 
studies, myeloablative conditioning, CMV viremia, acute 
GvHD grades 2–4 and in prospective studies, myeloabla-
tive conditioning and acute GvHD again  [15, 16] . How-
ever, the questions for proper risk stratification and when 
urological interventions are needed remain to be an-
swered.
 The most interesting result of our own analysis is that 
at the time of BK viruria, there seems to be an impairment 
of kidney function. From data of kidney transplanted pa-
tients, we know that there is also BK-associated nephrop-
athy, which can lead to acute renal failure and even graft 
loss  [16] . In patients after allogenic stem cell transplanta-
tion, a correlation between BK viruria and creatinine in-
crease or acute renal failure has not been demonstrated 
so far.
 To our current knowledge, BK virus is a polyomavirus 
that can lead to BK virus–associated haemorrhagic cysti-
tis especially in patients undergoing allogenic stem cell 
transplantation and to BK-virus associated nephropathy 
especially in kidney transplants. It is highly associated 
with the extent of immunosuppression  [10] . We believe 
that our data give a hint that BK virus infection during 
allogenic stem cell transplantation in adult patients can 
also lead to BK-associated nephropathy. Until today there 
is lack of data in this field.
 Of course (as in every retrospective study with a small 
sample size), we have to assume that our data are biased. 
On the one hand, 74% of the conditioning regimes used 
cyclophosphamide, which is highly nephrotoxic and can 
also lead to haemorrhagic cystitis, mostly earlier than the 
BK virus, till 14 days after transplantation  [10] . In mean 
the BK viruria occurred 28 days after transplantation in 
our population and in patients who had BK virus–associ-
ated cystitis even later (mean 35 days); so we assume that 
it is not linked to cyclophosphamide.
 On the other hand, we need more data about the im-
munosuppression and the use of nephrotoxic substances. 
CsA is always used for immunosuppression in our study 
population. That is why we suggest that the observed dif-
ferences in creatinine level are not due to its use in pa-
tients with BK viruria.
 The creatinine development in our study population 
( fig. 1 ) may be interpreted in the following way: the study 
population starts with a mean normal creatinine in both 
groups. With the start of the conditioning regimen, cre-
atinine levels fall to a lower normal level in both groups 
(patients with and without BK viruria) according to the 
higher fluid intake associated with application of the che-
motherapy and the infusion of the stem cell product. Af-
ter transplantation, mean creatinine rises again mainly 
due to nephrotoxic substances esp. in immunosuppres-
sion, but in the group of patients with BK viruria, its lev-
els stays high and we suggest that BK virus–associated 
 Fig. 2. Overall survival. 
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nephropathy is the reason. In the group of patients with-
out BK viruria, mean creatinine falls again even to a low-
er level. That might be due to the reduction of immuno-
suppression and due to a positive selection of patients 
who survived allogenic stem cell transplantation. Cer-
tainly, there are better ways to evaluate kidney function 
than enzymatic creatinine like in this study population, 
for example GFR, estimated GFR and Cystatin C; so we 
need further investigation on a prospective basis to evalu-
ate this issue in the right way.
 Because BK virus was assessed based only on clinical 
suspicion (which means presence of hemorrhagic cystitis 
in most cases), we may have missed out on subclinical re-
activations of BK virus without clinical symptoms. This 
problem will be addressed in an ongoing prospective trial.
 In our retrospective analysis, BK viruria is not linked 
to bacterial UTI in this group of patients; therefore, we 
think that BK virus infections are not co-infections with 
bacterial UTI.
 BK viruria is significantly linked to myeloablative con-
ditioning regimen and to donor mismatch. This might be 
explained by a higher degree of immunosuppression in 
patients with donor mismatch or myeloablative condi-
tioning. Previous studies also described myeloablative 
conditioning as a risk factor for BK-associated haemor-
rhagic cystitis  [2] .
 There was no mortality due to a urological problem. 
The overall survival data do not differ from what you 
would expect in a heterogenic group of adult allogenic 
stem cell transplantation patients  [1, 17] .
 Despite the aforementioned limitations, we believe that 
our study is important. It is the first analysis of allogenic 
stem cell transplantation in adult patients only focused on 
urological complications and it is the first study that dem-
onstrates a correlation between BK-viruria and acute renal 
failure in this population. Further investigations are neces-
sary, for example to identify more risk factors for urologi-
cal complications; so a proper risk stratification and even 
prevention of complications are possible. Still BK virus in-
fections under allogenic stem cell transplantation need 
more investigation since they can be a severe problem and 
no causal therapy has been established yet.
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